BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $45.00 price target on Novo Nordisk (NYSE: NVO)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)February 6, 2026 6:04 AM Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'February 5, 2026 10:25 AM